Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?
by
Aaron C. Gerlach * and Jeffrey L. Krajewski
Aaron C. Gerlach * and Jeffrey L. Krajewski
Icagen, Inc., 4222 Emperor Blvd, Durham, NC 27703, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(9), 2884-2899; https://doi.org/10.3390/ph3092884
Received: 19 August 2010 / Revised: 25 August 2010 / Accepted: 1 September 2010 / Published: 1 September 2010
Current marketed antiepileptic drugs (AEDs) consist of a variety of structural classes with different mechanisms of action. These agents typically have non-overlapping efficacy and side-effect profiles presenting multiple treatment options for the patient population. However, approximately 30% of seizure sufferers fail to respond to current therapies often because poorly tolerated side-effects limit adequate dosing. The scope of this review is to summarize selected advances in 2nd and 3rd generation AEDs as well as compounds in development with novel mechanisms of action.
View Full-Text
Keywords:
epilepsy; antiepileptic; AED; seizure; anticonvulsant
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License
MDPI and ACS Style
Gerlach, A.C.; Krajewski, J.L. Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going? Pharmaceuticals 2010, 3, 2884-2899.
Show more citation formats
